Eva Jack

Ms. Jack, a proven leader in the biopharmaceutical industry, brings a broad scope of business and operational experience to HotSpot Therapeutics. She has a highly successful track record in leading financings, forming and negotiating strategic collaborations, facilitating strategy development, and building and leading business, finance and other administrative functions.

She joined the team from Mersana Therapeutics, where she was the Chief Business Officer and played a major role in transforming the company from an early-stage start-up to a publicly traded, clinical-stage organization. She has also consulted with biotech companies and investors on business and financing strategies. Previously, she served as the Chief Business Officer of Pulmatrix, and before that, she was with Medlmmune (acquired by AstraZeneca). While at Medlmmune Ms. Jack was Managing Director of Medlmmune Ventures, where she was responsible for making and managing investments in private biotechnology companies. Prior to Medlmmune Ventures, she was in Medlmmune's Business Development group, where she was responsible for in- licensing, out-licensing and research collaborations. Prior to joining Medlmmune, Ms. Jack held a variety of positions at Intel Corporation, where she worked in venture investments, corporate strategy and public policy.

Ms. Jack holds a bachelor's degree from the University of Virginia and a master's degree in health sciences from The Johns Hopkins University. Additionally, she is a volunteer puppy raiser for Canine Companions for Independence@, a non- profit organization that enhances the lives of people with disabilities by providing highly trained assistance dogs.